Studies have shown that MYD88, CREBBP, and MYC mutations play a vital role in regulating apoptosis/cell proliferation and transcription and predict adverse clinical outcomes in DLBCL patients [34–36], which is consistent with our results. Here, CREBBP is linked to diffuse large B-cell lymphoma.